JP Morgan initiated coverage on Upstream Bio with a new price target
$UPB
Biotechnology: Pharmaceutical Preparations
Health Care
JP Morgan initiated coverage of Upstream Bio with a rating of Overweight and set a new price target of $38.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/5/2024 | $75.00 | Overweight | Piper Sandler |
| 11/5/2024 | $38.00 | Overweight | JP Morgan |
| 11/5/2024 | Outperform | William Blair | |
| 11/5/2024 | Buy | TD Cowen |
Piper Sandler initiated coverage of Upstream Bio with a rating of Overweight and set a new price target of $75.00
JP Morgan initiated coverage of Upstream Bio with a rating of Overweight and set a new price target of $38.00
William Blair initiated coverage of Upstream Bio with a rating of Outperform
– On track to report top-line data from Phase 2 trial in chronic rhinosinusitis with nasal polyps (CRSwNP) in the third quarter of 2025 – – Completed enrollment in Phase 2 trial in severe asthma in June 2025; top-line data expected in the first quarter of 2026 – – First patient dosed in Phase 2 trial in chronic obstructive pulmonary disease (COPD) in July 2025 – WALTHAM, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today reported financial results for the second quarter ended June 30, 2025, and provided a summary of re
Omega Funds, a leading international healthcare venture capital firm focused on delivering impactful medicines to patients, today announced the closing of its eighth fund with $647 million in capital commitments. The new fund, Omega Fund VIII, L.P. ("Fund VIII"), was oversubscribed, exceeding its target of $600 million, garnering strong support from both new and existing limited partners. With Fund VIII, the firm will continue to execute its strategy of creating and investing in innovative life sciences companies in the U.S. and Europe that target severe, unmet medical needs. Since its inception in 2004, Omega Funds has raised $2.5 billion to invest in exceptional entrepreneurs developing
– Global Phase 2 clinical trial, VENTURE, to evaluate the efficacy and safety of verekitug administered every 12 or 24 weeks in moderate-to-severe COPD – – Broadens global development program for verekitug into third indication, strengthening pipeline across severe respiratory diseases including chronic rhinosinusitis with nasal polyps (CRSwNP), severe asthma, and COPD – – Program updates also include completion of enrollment in Phase 2 clinical trial in severe asthma; top-line data now expected in first quarter of 2026 – WALTHAM, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an in
4 - Upstream Bio, Inc. (0002022626) (Issuer)
4 - Upstream Bio, Inc. (0002022626) (Issuer)
4 - Upstream Bio, Inc. (0002022626) (Issuer)
4 - Upstream Bio, Inc. (0002022626) (Issuer)
4 - Upstream Bio, Inc. (0002022626) (Issuer)
4 - Upstream Bio, Inc. (0002022626) (Issuer)
SCHEDULE 13G/A - Upstream Bio, Inc. (0002022626) (Subject)
10-Q - Upstream Bio, Inc. (0002022626) (Filer)
8-K - Upstream Bio, Inc. (0002022626) (Filer)
WALTHAM, Mass., May 20, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced the appointment of Stacy Price, MS, PMP, as Chief Technology Officer. Ms. Price brings over 25 years of experience in technical operations, manufacturing, and product development in the biotechnology industry, across a variety of drug modalities. In this role, Ms. Price will oversee the expansion of technical operations and product development in support of Upstream Bio's global development of verekitug, with a focus on chemistry, manufacturing, and controls (CMC) pr
WALTHAM, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (NASDAQ:UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that the Company has appointed Allison Ambrose, J.D. as General Counsel. Ms. Ambrose is a senior legal leader with more than 15 years of experience providing counsel on a wide range of matters including corporate governance, securities law and compliance, and capital markets and corporate development transactions. Ms. Ambrose will oversee all aspects of Upstream's legal function and join the Company's executive leadership team. "I am thrilled to welcome Allison to
SC 13G - Upstream Bio, Inc. (0002022626) (Subject)
SC 13D - Upstream Bio, Inc. (0002022626) (Subject)
SC 13G - Upstream Bio, Inc. (0002022626) (Subject)